Evidence map›Paper›PMID 39132327›Full record

ArticleCirculation reports2024

Impact of Cilostazol Administration on Prevention of Aspiration Pneumonia in Patients With Chronic Limb-Threatening Ischemia.

Yosuke Hata, Osamu Iida, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takuya Tsujimura, Naoko Higashino, Taku Toyoshima, Sho Nakao, Eisaku Ito and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yosuke HataCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Osamu IidaDivision of Cardiology, Osaka Police Hospital Osaka Japan.
Shin OkamotoCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Takayuki IshiharaCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Kiyonori NantoCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Takuya TsujimuraCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Naoko HigashinoDivision of Cardiology, Osaka University Graduate School of Medicine Osaka Japan.
Taku ToyoshimaDivision of Cardiology, Osaka Police Hospital Osaka Japan.
Sho NakaoCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.
Eisaku ItoDivision of Vascular Surgery, Department of Surgery, The Jikei University School of Medicine Tokyo Japan.
Takao OhkiDivision of Vascular Surgery, Department of Surgery, The Jikei University School of Medicine Tokyo Japan.
Toshiaki ManoCardiovascular Center, Kansai Rosai Hospital Hyogo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cilostazol has reported effectiveness for preventing aspiration pneumonia in patients with ischemic stroke, but whether it is similarly beneficial for patients with chronic limb-threatening ischemia (CLTI) is unclear. Methods and Results: This retrospective single-center study enrolled 1,368 CLTI patients treated with endovascular therapy (EVT). In the multivariate analysis, predictors for aspiration pneumonia were age (hazard ratio [HR] 1.06 [95% confidence interval (CI) 1.03-1.10]), non-ambulatory status (HR 2.54 [95% CI 1.38-4.65]), the Geriatric Nutritional Risk Index (HR 0.97 [95% CI 0.95-0.99]), and cilostazol (HR 0.37 [95% CI 0.16-0.87]). Conclusions: Cilostazol administration reduced the risk of aspiration pneumonia in patients with CLTI undergoing EVT.

Indexed as

Aspiration pneumoniaChronic limb-threatening ischemiaCilostazol

Identifiers

PMID39132327
PMCPMC11309771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.